Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OBINUTUZUMAB vs OCRELIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OBINUTUZUMAB vs OCRELIZUMAB: Safety Overview

Metric OBINUTUZUMAB OCRELIZUMAB
Total FAERS Reports 14,189 56,186
Deaths Reported 1,919 1,406
Death Rate 13.5% 2.5%
Hospitalizations 5,419 10,364
Average Patient Age 63.8 yrs 47.2 yrs
% Female Patients 41.7% 72.5%
Manufacturer Genentech, Inc. Genentech, Inc.
Route INTRAVENOUS INTRAVENOUS
Marketing Status Prescription Prescription